Generic Rapiblyk Availability
Last updated on Sep 10, 2025.
Rapiblyk is a brand name of landiolol, approved by the FDA in the following formulation(s):
RAPIBLYK (landiolol hydrochloride - powder;intravenous)
-
Manufacturer: AOP ORPHAN
Approval date: November 22, 2024
Strength(s): EQ 280MG BASE/VIAL [RLD]
Is there a generic version of Rapiblyk available?
No. There is currently no therapeutically equivalent version of Rapiblyk available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Rapiblyk. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
Patent 10,722,516
Issued: July 28, 2020
Inventor(s): Krumpl; Günther
Assignee(s): AOP ORPHAN PHARMACEUTICALS AG (Vienna, AT)The invention provides a new use of landiolol hydrochloride for persistent reduction of the heart rate during the administration period of landiolol hydrochloride in the treatment of a human suffering from tachycardia, tachyarrhythmia or elevated blood pressure, wherein landiolol hydrochloride is administered at a constant dose of more than 5 μg/kg/min, specifically of at least 10 μg/kg/min for a period of at least 2 hours and wherein the heart rate and/or blood pressure of said patient are persistently reduced during the administration period compared to the heart rate and/or blood pressure before treatment and no overshooting effect occurs after termination of said administration.
Patent expiration dates:
- April 25, 2034✓
- April 25, 2034
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- November 22, 2029 - NEW CHEMICAL ENTITY
More about Rapiblyk (landiolol)
- Check interactions
- Compare alternatives
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: cardioselective beta blockers
- En español
Patient resources
Professional resources
Related treatment guides
Related/similar drugs
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
